Showing results (571-580 of 831) with videos related to
Sort By:
Pageof 84
Investigational New Drugs|June 10, 2010
The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cellsWei-Gang Tong, Zeev Estrov, Yongtao Wang, et al.Journal of Immunology (Baltimore, Md. : 1950)|August 19, 2016
Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic LeukemiaElisa Ten Hacken, Mariela Sivina, Ekaterina Kim, et al.British Journal of Haematology|October 3, 2002
Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndromeNaoto T Ueno, Athanasios Anagnostopoulos, Gabriela Rondón, et al.Blood|January 13, 2006
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or olderStefan Faderl, Srdan Verstovsek, Jorge Cortes, et al.Clinical Lymphoma, Myeloma & Leukemia|April 27, 2012
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemiaElias Jabbour, Guillermo Garcia-Manero, Jorge Cortes, et al.Blood Cancer Journal|August 10, 2020
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burdenDaniel J DeAngelo, Anjali S Advani, David I Marks, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2009
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatmentWilliam G Wierda, Susan O'Brien, Xuemei Wang, et al.British Journal of Haematology|February 6, 2016
Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomesPreetesh Jain, Hagop Kantarjian, Koji Sasaki, et al.BMC Medical Genetics|November 17, 2010
Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndromeWanlong Ma, Hagop Kantarjian, Ke Zhang, et al.Cancer|December 15, 2005
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimensWilliam Wierda, Susan O'brien, Stefan Faderl, et al.Pageof 84